Omeros Corporation (OMER) will soon begin two mid stage clinical trials on its drug OMS824 which has greatly increased its stock prices. The company is testing its drug as a treatment for Huntington’s disease toward the end of 2013 as well as trials involved the treatment of Schizophrenia.
Earlier this month, a team of researchers led by the University of Colorado at Boulder announced that the inhalable measles vaccine they developed could lead to vaccines for other diseases.
Compliance is a vital part of managing mental health issues, considering the widespread use of psychiatric medications in the U.S.
Alexza Pharmaceuticals of Mountain View, Calif., is focused on the development of inhalation drugs for the treatment of central nervous system disorders.
Acadia and its partner Biovail made news last month with a failed late-stage trial of pimavanserin, their experimental drug candidate to treat psychosis related to Parkinson’s disease.
The U.S. Food and Drug Administration has approved Janssen Pharmaceuticals’ Invega Sustenna for acute and maintenance treatment of schizophrenia.
Maryland-based Vanda Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Fanapt (otherwise known as iloperidone) for the acute treatment of adult patients with schizophrenia.
Copyright © 2025 | WordPress Theme by MH Themes